NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 203)
Posted On: 02/26/2021 4:13:18 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Looks to AI to Improve Clinical Decision Making for Ovarian Cancer Patients
Predictive Oncology (NASDAQ: POAI), through its wholly owned subsidiary, Helomics, has sought to end the alarming statistics surrounding ovarian cancer. According to figures provided by the American Cancer Society and quoted by an article discussing POAI’s motivations and operations, “an estimated 21,750 women received a new diagnosis of ovarian cancer this year (2020), and almost 14,000 women will die from the disease. Those numbers make ovarian cancer the fifth-leading cause of cancer deaths in women.” In a bid to change this reality, Predictive Oncology, a company that focuses on using data and artificial intelligence to develop personalized cancer therapies, has partnered with the University of Pittsburg School of Medicine, through Helomics, “to study the use of artificial intelligence (‘AI’) to improve clinical decision making for ovarian cancer patients. The collaboration entails using Helomics’ AI platform and proprietary data to analyze the genomic and drug response profiles of women with ovarian cancer to evaluate predictive values in terms of response and non-response to different treatments… Helomics’ predictive models will save time and money in the search for new targeted therapies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), through its wholly owned subsidiary, Helomics, has sought to end the alarming statistics surrounding ovarian cancer. According to figures provided by the American Cancer Society and quoted by an article discussing POAI’s motivations and operations, “an estimated 21,750 women received a new diagnosis of ovarian cancer this year (2020), and almost 14,000 women will die from the disease. Those numbers make ovarian cancer the fifth-leading cause of cancer deaths in women.” In a bid to change this reality, Predictive Oncology, a company that focuses on using data and artificial intelligence to develop personalized cancer therapies, has partnered with the University of Pittsburg School of Medicine, through Helomics, “to study the use of artificial intelligence (‘AI’) to improve clinical decision making for ovarian cancer patients. The collaboration entails using Helomics’ AI platform and proprietary data to analyze the genomic and drug response profiles of women with ovarian cancer to evaluate predictive values in terms of response and non-response to different treatments… Helomics’ predictive models will save time and money in the search for new targeted therapies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)